Tumor-specific targeting for the future of cell therapy
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
Our approach addresses the central problem of cancer research: tumor-targeted killing. We focus on targets either lost or gained in cancer cells, potentially creating breakthrough therapies to treat most cancers.
Our science & technology
Lack of tractable, novel targets is arguably the most important factor that has limited the development of new medicines over the past decades. At A2 we have both the technology and capabilities to discover potent and exquisitely selective molecules that bind under-explored and challenging targets.